News Sentiment

JNJ sentiment intelligence

Johnson & Johnson news scored across direct company coverage, industry context, sector read-through, source quality, and freshness.

Chart Weekly report Factors Options RSS feed
Weighted score 55 Balanced news tone 55 relevant articles
Exchange NYSE United States
Sector Healthcare Market context
Industry Drug Manufacturers - General Read-through group
Latest close 256.98 Week of 10 Jul 2026
Weighted tone 55/100

Balanced news tone

Market reaction Balanced read

News tone and price action are not far from neutral.

Primary event Market update

78/100 classification confidence.

Company focus 55

directly relevant articles

Source quality 6

high-authority source matches

Trend context Trend active

-2.3% over one week, +6.7% over four weeks, trend active, and materially above fair value.

Latest direct headline Positive

Goldman Sachs Adjusts Price Target on Johnson & Johnson to $282 From $275, Maintains Buy Rating

Market Reaction

Balanced read

63/100 confidence

News tone and price action are not far from neutral.

Primary event Market update 78/100 classification
One-week reaction -2.3% Price reacting lower
Trend fit Trend active 6.7% over four weeks
Fair value 52.4% Materially above fair value

Sentiment Mix

Positive, neutral, negative

Weighted by relevance
Positive 21
Neutral 30
Negative 4

Relevance

Why the article matched

Direct first
Direct company coverage 55
Industry context 0
Sector context 0

Sources

Coverage mix

Publishers
MarketBeat 12
MT Newswires 8
Market source 8
simplywall.st 5
Morningstar 2
Barron's 2
BioSpace 2
Fierce Biotech 2

Event Lens

What the news is about

Classified themes
Market update 29
Earnings 15
Analyst action 8
Guidance 2
Macro sensitivity 1

Sentiment Trail

Score over time

50 baseline
Above 50 Neutral zone Below 50

News Tape

Relevant headlines

Showing 1-30 of 55
Fox Business Direct company coverage

Johnson & Johnson commits to $55B, 4-year US investment plan

Johnson & Johnson's CFO Joe Wolk announced the company's commitment to a $55 billion, four-year investment plan in the US. Wolk discussed this plan, along with the company's Q2 earnings and the performance of its medical technology unit, including Impella heart pumps, during an i

Tone
Positive 71/100
Event
Earnings
Published
15 Jul 2026 20:07
Source
Fox Business
Morningstar Direct company coverage

Johnson & Johnson Earnings: Steady Growth and Good Near-Term Visibility

Johnson & Johnson reported a 6.6% revenue growth in the second quarter, driven by strong performances in Innovative Medicine and MedTech, leading management to increase 2026 guidance. While shares dropped 2% intraday, Morningstar is maintaining its $190 fair value estimate, notin

Tone
Positive 61/100
Event
Earnings
Published
15 Jul 2026 19:15
Source
Morningstar
BioSpace Direct company coverage

Amid $55B US manufacturing push, J&J turns to streamlining its pharma supply chain

Johnson & Johnson is restructuring its pharmaceutical supply chain, announcing up to $750 million in costs to streamline operations, including offloading certain sites. This move follows a $55 billion commitment to bolster U.S. manufacturing capabilities for medicines in the U.S.

Tone
Positive 67/100
Event
Macro sensitivity
Published
15 Jul 2026 17:56
Source
BioSpace
BioSpace Direct company coverage

Johnson & Johnson Announces Quarterly Dividend for Third Quarter 2026

Johnson & Johnson (NYSE: JNJ) has declared a cash dividend of $1.34 per share for the third quarter of 2026. This dividend will be payable on September 8, 2026, to shareholders recorded by August 25, 2026. The ex-dividend date is also set for August 25, 2026.

Tone
Positive 71/100
Event
Earnings
Published
15 Jul 2026 17:08
Source
BioSpace
Proactive financial news Direct company coverage

Johnson & Johnson’s Spravato sales growth supports psychedelic drug opportunity: Jefferies

Jefferies notes that strong Q2 sales of Johnson & Johnson's Spravato, a depression treatment, indicate a promising long-term commercial opportunity for psychedelic drugs in treating mental health disorders. The drug's annual revenue run rate of over $2.3 billion and its potential

Tone
Positive 71/100
Event
Earnings
Published
15 Jul 2026 15:34
Source
Proactive financial news
Fierce Pharma Direct company coverage

No patent protection for Stelara? No problem for J&J as Tremfya fills the void

Johnson & Johnson has increased its annual sales guidance after a strong second quarter, largely driven by the performance of its immunology portfolio. Despite a significant drop in Stelara sales due to patent expiry, the company's new drug Tremfya largely compensated for the dec

Tone
Positive 74/100
Event
Earnings
Published
15 Jul 2026 15:30
Source
Fierce Pharma
Market source Direct company coverage

J&J raises FY26 outlook following positive Q2

Johnson & Johnson (J&J) reported strong Q2 revenues of $25.3 billion, a 6.6% year-over-year increase, primarily driven by its Innovative Medicine business and J&J MedTech. Following these results, the company raised its 2026 earnings outlook to $11.60-$11.75 per share. Despite th

Tone
Positive 64/100
Event
Earnings
Published
15 Jul 2026 15:13
Source
Market source
Fierce Biotech Direct company coverage

J&J axes eye disease gene therapy after key phase 2b readout

Johnson & Johnson has discontinued the development of JNJ-1887, an eye disease gene therapy for geographic atrophy, after reviewing topline data from its phase 2b Parasol study. The company had acquired the asset in 2020 and initiated the 305-subject trial in 2023, aiming to slow

Tone
Negative 28/100
Event
Market update
Published
15 Jul 2026 14:38
Source
Fierce Biotech
Fierce Biotech Direct company coverage

J&J MedTech growth slows again in Q2 as Abiomed weighs on results

Johnson & Johnson's MedTech business experienced a slowdown in Q2 operational sales growth to 3.6%, reaching $8.93 billion, primarily due to ongoing challenges with Abiomed. Abiomed, acquired by J&J in 2022, saw its sales fall 2% year over year in the quarter, largely attributed

Tone
Negative 29/100
Event
Earnings
Published
15 Jul 2026 13:57
Source
Fierce Biotech
MassDevice Direct company coverage

Johnson & Johnson MedTech sales grow 4.5% in Street-beating Q2, ups guidance

Johnson & Johnson (J&J) reported strong Q2 2026 results, surpassing Wall Street expectations with 4.5% growth in MedTech sales and overall sales of $25.3 billion. The company also raised its full-year revenue and adjusted EPS guidance, now expecting annual revenue to exceed $100

Tone
Positive 80/100
Event
Earnings
Published
15 Jul 2026 10:54
Source
MassDevice
Johnson & Johnson Direct company coverage

Johnson and Johnson Earnings Report | 2026 Q2 Infographic

Johnson & Johnson released its second-quarter 2026 earnings report, highlighting strong performance in its Innovative Medicine and MedTech businesses. The company reported a 6.6% increase in sales to $25.3 billion, with operational growth of 5.6%, and an adjusted EPS of $2.90. Jo

Tone
Positive 73/100
Event
Earnings
Published
15 Jul 2026 10:41
Source
Johnson & Johnson
The Manila Times Direct company coverage

Genmab Announces Net Sales of DARZALEX® (daratumumab) for Second Quarter of 2026

Genmab announced that worldwide net trade sales of DARZALEX (daratumumab) for the second quarter of 2026 totaled USD 4,207 million. This figure includes sales of both intravenous and subcutaneous products, as reported by Johnson & Johnson. Genmab receives royalties on these globa

Tone
Positive 71/100
Event
Earnings
Published
15 Jul 2026 10:40
Source
The Manila Times